As part of our series focussing on medicines available in Australia, this review provides a clinical overview of the efficacy, safety, and durability of response of delgocitinib by drawing from the pivotal Phase 3 trials.
Guiding commentary has been provided by Associate Professor John Frew, a clinical dermatologist in Sydney, Australia, Director of Research at the Skin Hospital in Darlinghurst and Associate Professor of Dermatology at UNSW.
Please login below to download this issue (PDF)